首页> 外文期刊>Journal of chromatography, B. Analytical technologies in the biomedical and life sciences >Simultaneous analysis of the total plasma concentration of atorvastatin and its five metabolites and the unbound plasma concentration of atorvastatin: Application in a clinical pharmacokinetic study of single oral dose☆
【24h】

Simultaneous analysis of the total plasma concentration of atorvastatin and its five metabolites and the unbound plasma concentration of atorvastatin: Application in a clinical pharmacokinetic study of single oral dose☆

机译:同时分析阿托伐他汀及其五种代谢物的总血浆浓度及阿托伐他汀的未结血浆浓度:应用在单口服剂量☆的临床药代动力学研究☆

获取原文
获取原文并翻译 | 示例
           

摘要

Atorvastatin (ATV) and its two active metabolites, o-hydroxy atorvastatin acid (o-OH-ATV) and p-hydroxy atorvastatin acid (p-OH-ATV) are responsible for its HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme-A) reductase inhibitory activity, while its corresponding inactive lactone forms (LAC) are related to the manifestation of myopathy. The present study reports the development and validation of a method for the simultaneous analysis of ATV and its five metabolites (o-OH-ATV, p-OH-ATV, ATV-LAC, o-OH-ATV-LAC, p-OH-ATV-LAC) as total plasma concentration and ATV as unbound plasma concentration using UPLC-MS/MS. The method was applied in a pharmacokinetic study following administration of a single oral 20, 40 or 80 mg ATV dose in healthy volunteers (n=15). ATV and its five metabolites were separated on a C18 column using as mobile phase a mixture of 0.2% formic acid and acetonitrile (55:45, v/v) at a flow of 0.4 mL/min. The method showed linearity from 25 pg/mL to 200 ng/mL plasma as total concentration and from 6.25 pg to 25 ng/mL plasma ultrafiltrate as ATV unbound concentration. The coefficients of variation and the relative standard errors of the accuracy and precision analyses were<15%. The method allowed quantification of plasma concentrations of ATV and its five metabolites up to 36 h after 20, 40 or 80 mg ATV administration. The pharmacokinetic parameters dose normalized to 20 mg are presented as follow (n=15, mean): unbound fraction 9.38%, maximum plasma concentration 9.52 ng/mL, time to reach maximum plasma concentration 0.98 h, apparent total clearance 742.90 L/ h, apparent distribution volume 9005 L, and AUC metabolite/ATV ratios 0.06 for p-OH-ATV, 0.94 for o-OH-ATV, 1.43 for ATV-LAC, 0.25 for p-OH-ATV-LAC and 1.75 for o-OH-ATV-LAC. In conclusion, the methods for simultaneous analysis of ATV and its five metabolites as total plasma concentration and ATV as the unbound plasma concentration showed sensitivity, linearity, precision and accuracy compatible with appl
机译:阿托伐他汀(ATV)及其两种活性代谢物,O-羟基阿托伐他汀酸(O-OH-ATV)和P-羟基阿托伐他汀酸(P-OH-ATV)负责其HMG-COA(3-羟基-3-甲基utaryl - 酶-A)还原酶抑制活性,而其相应的非活性内酯形式(LAC)与肌病的表现有关。本研究报告了ATV及其五种代谢物同时分析的方法的开发和验证(O-OH-ATV,P-OH-ATV,ATV-LAC,O-OH-ATV-LAC,P-OH- ATV-LAC)作为使用UPLC-MS / MS的总血浆浓度和ATV作为未结血浆浓度。在施用单个口服20,40或80mg ATV剂量的药代动力学研究中施用该方法在健康志愿者(n = 15)。使用0.2%甲酸和乙腈(55:45,V / V)的流动相,在C18柱上在C18柱上分离ATV及其五种代谢物。在0.4ml / min的流动下。该方法显示出从25pg / ml至200ng / ml等离子体的线性度,作为总浓度,从6.25pg至25ng / ml等离子体超滤液作为ATV未结合浓度。变异系数和精度和精度分析的相对标准误差<15%。该方法允许定量血浆浓度的ATV及其五种代谢物,在20,40或80mg ATV给药后高达36小时。标准化为20mg的药代动力学参数剂量如下介绍(n = 15,平均值):未结合级分9.38%,最大等离子体浓度9.52ng / ml,时间达到最大血浆浓度0.98h,表观总间隙742.90 L / h,对于对OH-ATV,0.94的O-OH-ATV,1.43用于ATV-LAC,0.25,对于O-OH-ATV-LAC,1.75,对于O-OH-ATV-LAC,0.25,对于O-OH-ATV-LAC,0.25,对于O-OH-ATV-LAC,1.75,对于O-OH-ATV-LAC,0.25的AUC代谢物/ ATV比率0.06。 ATV-LAC。总之,随着血浆浓度的总血浆浓度和ATV同时分析ATV及其五种代谢物的方法显示敏感性,线性,精度和准确性与APPL兼容

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号